Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q4 EPS by 11c; Issues FY13 Outlook
Tweet Send to a Friend
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q4 EPS of $1.53, $0.11 better than the analyst estimate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
